Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients
- Conditions
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT00375076
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2531
- Registration Number
- NCT00361894
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3148
- Registration Number
- NCT00362232
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
- Conditions
- Interventions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Medical Compression Systems
- Target Recruit Count
- 411
- Registration Number
- NCT00358735
- Locations
- 🇺🇸
The center for hip and knee surgery, Mooresville, Indiana, United States
🇺🇸The Center Orthopedic & Neurosurgical Care &Research, Bend, Oregon, United States
🇺🇸Empire Orthopedic Center, Loma Linda, California, United States
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
- Conditions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 156
- Registration Number
- NCT00349180
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3202
- Registration Number
- NCT00345618
- Locations
- 🇷🇺
Sanofi-Aventis Admnistrative Office, Moscow, Russian Federation
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 705
- Registration Number
- NCT00331838
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2457
- Registration Number
- NCT00332020
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
- Conditions
- Interventions
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4541
- Registration Number
- NCT00329628
LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 60
- Registration Number
- NCT00321009
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Doylestown Hospital, Doylestown, Pennsylvania, United States
🇺🇸LaBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.